AstraZeneca completes acquisition of TeneoTwo
AstraZeneca has acquired all outstanding equity of TeneoTwo in exchange for an upfront payment of $100 million
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
TeneoTwo
AstraZeneca to acquire TeneoTwo
NB-486 will be evaluated in multiple types of lymphoma